Technology To Improve the Robustness of Diagnostic Assays

提高诊断分析稳健性的技术

• 批准号: 522042-2017
• 负责人: Uludag, Hasan
• 金额: $ 1.82万
• 依托单位: University of Alberta
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=640599
• 关键词: Technology; Improve; Robustness; Diagnostic; Assays

Minimally invasive diagnostic analyses that do not require tissue sampling is a desirable approach for detectionof wide range of diseases, including invasive pathogens. RNA-based biomarkers from these pathogens arereleased to the bloodstream and become part of the cell free RNA pool in blood, making them promising fordisease detection. These biomarkers, however, usually exist in small amounts and are exceptionally fragile. Insituations where the storage conditions of the blood sample fall outside optimal handling conditions, the qualityof the samples is compromised, thereby decreasing the sensitivity and accuracy of biomarker analysis. We areproposing a novel system that entails nucleic acid binding polymers to stabilize RNA markers present in bloodto prevent their degradation under non-optimal temperature and processing (time) conditions. It is envisionedthat the blood samples treated with the stabilizing agents and subsequent analysis can be carried out withoutsample degradation. Upon successful completion of this project, our industrial partner Aquila DiagnosticSystems Inc. is expected to launch of the new blood collection system that will result in a new source ofrevenue and increase the job creation in Canada.

不需要组织取样的微创诊断分析是检测包括侵袭性病原体在内的多种疾病的理想方法。来自这些病原体的基于 RNA 的生物标志物被释放到血流中，并成为血液中无细胞 RNA 库的一部分，这使得它们有望用于疾病检测。然而，这些生物标志物通常含量很少并且非常脆弱。当血液样本的储存条件超出最佳处理条件时，样本的质量就会受到影响，从而降低生物标志物分析的灵敏度和准确性。我们提出了一种新的系统，该系统需要核酸结合聚合物来稳定血液中存在的 RNA 标记，以防止它们在非最佳温度和处理（时间）条件下降解。预计用稳定剂处理的血液样品和随后的分析可以在样品不降解的情况下进行。该项目成功完成后，我们的工业合作伙伴 Aquila DiagnosticSystems Inc. 预计将推出新的血液采集系统，这将为加拿大带来新的收入来源并增加就业机会。